148 related articles for article (PubMed ID: 15849263)
1. Lamivudine prophylaxis in HBV carriers with haemato-oncological malignancies who receive chemotherapy.
Idilman R
J Antimicrob Chemother; 2005 Jun; 55(6):828-31. PubMed ID: 15849263
[TBL] [Abstract][Full Text] [Related]
2. Anti-viral prophylaxis in inactive hepatitis B virus carriers with hemato-oncological malignancies who receive chemotherapy.
Idilman R
Minerva Gastroenterol Dietol; 2006 Mar; 52(1):39-45. PubMed ID: 16554705
[TBL] [Abstract][Full Text] [Related]
3. Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy--a prospective case series.
Vassiliadis T; Garipidou V; Tziomalos K; Perifanis V; Giouleme O; Vakalopoulou S
Am J Hematol; 2005 Nov; 80(3):197-203. PubMed ID: 16247746
[TBL] [Abstract][Full Text] [Related]
4. A possible role for lamivudine as prophylaxis against hepatitis B reactivation in carriers of hepatitis B who undergo chemotherapy and autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma.
Endo T; Sakai T; Fujimoto K; Yamamoto S; Takashima H; Haseyama Y; Nishio M; Koizumi K; Koike T; Sawada K
Bone Marrow Transplant; 2001 Feb; 27(4):433-6. PubMed ID: 11313673
[TBL] [Abstract][Full Text] [Related]
5. Antiviral prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection.
Kohrt HE; Ouyang DL; Keeffe EB
Clin Liver Dis; 2007 Nov; 11(4):965-91, x. PubMed ID: 17981237
[TBL] [Abstract][Full Text] [Related]
6. Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies.
Idilman R; Arat M; Soydan E; Törüner M; Soykan I; Akbulut H; Arslan O; Ozcan M; Türkyilmaz AR; Bozdayi M; Karayalçin S; Van Thiel DH; Ozden A; Beksaç M; Akan H
J Viral Hepat; 2004 Mar; 11(2):141-7. PubMed ID: 14996349
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis B virus reactivation in patients receiving chemotherapy for cancer treatment: role of Lamivudine prophylaxis.
Coiffier B
Cancer Invest; 2006; 24(5):548-52. PubMed ID: 16939967
[TBL] [Abstract][Full Text] [Related]
8. Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients.
Hsiao LT; Chiou TJ; Liu JH; Chu CJ; Lin YC; Chao TC; Wang WS; Yen CC; Yang MH; Tzeng CH; Chen PM
Biol Blood Marrow Transplant; 2006 Jan; 12(1):84-94. PubMed ID: 16399572
[TBL] [Abstract][Full Text] [Related]
9. Lamivudine facilitates optimal chemotherapy in hepatitis B virus-infected children with hematological malignancies: a preliminary report.
el-Sayed MH; Shanab G; Karim AM; el-Tawil A; Black A; Dixon JS
Pediatr Hematol Oncol; 2004 Mar; 21(2):145-56. PubMed ID: 15160513
[TBL] [Abstract][Full Text] [Related]
10. [Nucleos(t)ides as prophylaxis for the reactivation of hepatitis B virus in immunosuppressed patients].
Fan LY; Zhou Z; Zhong S; Ling N; Wang ZY; Shi XF; Zhang DZ; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2009 Jun; 17(6):429-33. PubMed ID: 19567021
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy.
Koo YX; Tan DS; Tan IB; Tao M; Chow WC; Lim ST
Cancer; 2010 Jan; 116(1):115-21. PubMed ID: 19899164
[TBL] [Abstract][Full Text] [Related]
12. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma.
Li YH; He YF; Jiang WQ; Wang FH; Lin XB; Zhang L; Xia ZJ; Sun XF; Huang HQ; Lin TY; He YJ; Guan ZZ
Cancer; 2006 Mar; 106(6):1320-5. PubMed ID: 16470607
[TBL] [Abstract][Full Text] [Related]
13. Fatal reactivation of hepatitis B virus in a patient who was hepatitis B surface antigen negative and core antibody positive before receiving chemotherapy for non-Hodgkin lymphoma.
Wu JM; Huang YH; Lee PC; Lin HC; Lee SD
J Clin Gastroenterol; 2009; 43(5):496-8. PubMed ID: 19247200
[TBL] [Abstract][Full Text] [Related]
14. Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature.
Zingarelli S; Frassi M; Bazzani C; Scarsi M; Puoti M; Airò P
J Rheumatol; 2009 Jun; 36(6):1188-94. PubMed ID: 19447932
[TBL] [Abstract][Full Text] [Related]
15. Duration of lamivudine prophylaxis in inactive hepatitis B virus carriers with haemato/oncological malignancies who receive chemotherapy.
Idilman R
Gut; 2006 Aug; 55(8):1208-9. PubMed ID: 16849352
[No Abstract] [Full Text] [Related]
16. The effectiveness of lamivudine in preventing hepatitis B viral reactivation in rituximab-containing regimen for lymphoma.
He YF; Li YH; Wang FH; Jiang WQ; Xu RH; Sun XF; Xia ZJ; Huang HQ; Lin TY; Zhang L; Bao SP; He YJ; Guan ZZ
Ann Hematol; 2008 Jun; 87(6):481-5. PubMed ID: 18299831
[TBL] [Abstract][Full Text] [Related]
17. The controversial role of lamivudine prophylaxis in occult HBV carriers treated with chemo-immune therapy.
D'Andrea M; Nosotti L; Pimpinelli F; Dessanti ML; Paviglianiti A; Miglioresi L; Morrone A; Petti MC
Dig Liver Dis; 2009 Nov; 41(11):839-40. PubMed ID: 19464241
[No Abstract] [Full Text] [Related]
18. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients.
Yeo W; Ho WM; Hui P; Chan PK; Lam KC; Lee JJ; Johnson PJ
Breast Cancer Res Treat; 2004 Dec; 88(3):209-15. PubMed ID: 15609123
[TBL] [Abstract][Full Text] [Related]
19. [Effect of lamivudine for hepatitis B virus reactivation in blood cancer patients undergoing immunosuppressive chemotherapy].
Sugimoto R; Enjoji M; Kotoh K; Noguchi K; Tsuruta S; Nakamuta M; Nawata H
Fukuoka Igaku Zasshi; 2004 Oct; 95(10):274-9. PubMed ID: 15678886
[TBL] [Abstract][Full Text] [Related]
20. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies.
Lalazar G; Rund D; Shouval D
Br J Haematol; 2007 Mar; 136(5):699-712. PubMed ID: 17338776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]